Archives

Novel GLP-1 Pill Tops Oral Semaglutide for Diabetes

(MedPage Today) — An investigational GLP-1 receptor agonist pill edged out oral semaglutide (Rybelsus) for improving blood glucose in adults with type 2 diabetes inadequately controlled on metformin, the phase III ACHIEVE-3 trial showed.
Among…

Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had heart failure. The findings, published in JAMA Internal Medicine, come from a large randomized trial of nearly 9,650 adults who have both type 2 diabetes and either cardiovascular disease or chronic kidney disease. Researchers followed participants for nearly four years as part of the Semaglutide Cardiovascular Outcomes, or SOUL, Trial. The results are from a secondary analysis of those data.

Jiuyuan seeks approval of Wegovy biosimilar in China

China’s National Medical Products Administration (NMPA) has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity.

New GLP-1 pill helps patients lose up to 8% of body weight, trial shows

Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabsA new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for an improved non-injection alternative to Wegovy and Mounjaro.The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide. Like semaglutide, it lowers blood sugar levels, slows digestion and suppresses appetite. Unlike semaglutide tablets, it does not need to be taken on an empty stomach. Continue reading…

New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year than the current available oral GLP-1 RA (semaglutide), finds a phase 3 randomized controlled trial published in The Lancet. Additionally, participants taking orforglipron had significantly greater reductions in body weight than those taking oral semaglutide.